NeuroImmunology
8.2K views | +1 today
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease

Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease | NeuroImmunology | Scoop.it
Sphingolipids are important in many brain functions but their role in Alzheimer’s disease (AD) is not completely defined. A major limit is availability of fresh brain tissue with defined AD pathology.

Via Krishan Maggon
Krishan Maggon 's curator insight, May 5, 2015 5:50 AM

Citation: Fonteh AN, Ormseth C, Chiang J, Cipolla M, Arakaki X, et al. (2015) Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease. PLoS ONE 10(5): e0125597. doi:10.1371/journal.pone.0125597

Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century* | Journal of Neurology and Neurological Dis...

Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century* | Journal of Neurology and Neurological Dis... | NeuroImmunology | Scoop.it
The amyloid precursor protein (APP) is mainly known for being the precursor of the ß-amyloid peptide, which accumulates in plaques found in the brain of Alzheimer's disease patients.

Via Krishan Maggon
Krishan Maggon 's curator insight, November 16, 2014 3:21 AM
Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century*Franco R , Navarro G, Martínez-Pinilla E and Moreno E JOURNAL OF NEUROLOGY AND NEUROLOGICAL DISORDERS

Copyright: © 2014 Franco R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease

Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease | NeuroImmunology | Scoop.it

The present study explored the extent and characteristics of intraneuronal amyloid-β accumulation, particularly of the fibrillogenic 42-amino acid isoform, within basal forebrain cholinergic neurons in normal young, normal aged and Alzheimer’s disease brains as a potential contributor to the selective vulnerability of these neurons using immunohistochemistry and western blot analysis. Amyloid-β1–42immunoreactivity was observed in the entire cholinergic neuronal population regardless of age or Alzheimer’s disease diagnosis. The magnitude of this accumulation as revealed by optical density measures was significantly greater than that in cortical pyramidal neurons, and magnocellular neurons in the globus pallidus did not demonstrate a similar extent of amyloid immunoreactivity. Immunoblot analysis with a panel of amyloid-β antibodies confirmed accumulation of high concentration of amyloid-β in basal forebrain early in adult life. There was no age- or Alzheimer-related alteration in total amyloid-β content within this region. In contrast, an increase in the large molecular weight soluble oligomer species was observed with a highly oligomer-specific antibody in aged and Alzheimer brains when compared with the young. Similarly, intermediate molecular weight oligomeric species displayed an increase in aged and Alzheimer brains when compared with the young using two amyloid-β42 antibodies. Compared to cortical homogenates, small molecular weight oligomeric species were lower and intermediate species were enriched in basal forebrain in ageing and Alzheimer’s disease. Regional and age-related differences in accumulation were not the result of alterations in expression of the amyloid precursor protein, as confirmed by both immunostaining and western blot. Our results demonstrate that intraneuronal amyloid-β accumulation is a relatively selective trait of basal forebrain cholinergic neurons early in adult life, and increases in the prevalence of intermediate and large oligomeric assembly states are associated with both ageing and Alzheimer’s disease. Selective intraneuronal amyloid-β accumulation in adult life and oligomerization during the ageing process are potential contributors to the degeneration of basal forebrain cholinergic neurons in Alzheimer’s disease.


Via Krishan Maggon
Krishan Maggon 's curator insight, March 3, 2015 11:55 AM

Beta amyloid was detected in younger brains 20 yr of age.

 

 

Brain  

 

Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease

 

Alaina Baker-Nigh , Shahrooz Vahedi , Elena Goetz Davis , Sandra Weintraub , Eileen H. Bigio , William L. Klein , Changiz GeulaDOI: http://dx.doi.org/10.1093/brain/awv024 First published online: 2 March 2015
Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Molecular Neurodegeneration | Full text | Immunotherapy for Alzheimer's disease: hoops and hurdles

Alzheimer’s disease (AD) is the most common form of dementia, afflicting more than 30 million people worldwide. Currently, there is no cure or way to prevent this devastating disease.

Via Krishan Maggon
Gilbert C FAURE's insight:
Abstract

.... Extracellular plaques, containing various forms of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein, are two major pathological hallmarks of the AD brain. Aggregation, deposition, and N-terminal modification of Aβ protein and tau phosphorylation and aggregation are thought to precede the onset of cognitive decline, which is better correlated with tangle formation and neuron loss. Active and passive vaccines against various forms of Aβ have shown promise in pre-clinical animal models. However, translating these results safely and effectively into humans has been challenging. Recent clinical trials showed little or no cognitive efficacy, possibly due to the fact that the aforementioned neurodegenerative processes most likely pre-existed in the patients well before the start of immunotherapy. Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease. In addition, efforts to immunize against tau and other AD-related targets are underway.

Krishan Maggon 's curator insight, November 2, 2014 1:56 AM

Review

Immunotherapy for Alzheimer’s disease: hoops and hurdles

Cynthia A Lemere

Correspondence: Cynthia A Lemere clemere@partners.org

Author Affiliations

Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, NRB 636F, 77 Avenue Louis Pasteur, Boston 02115, MA, USA

Molecular Neurodegeneration 2013, 8:36  doi:10.1186/1750-1326-8-36


The electronic version of this article is the complete one and can be found online at:http://www.molecularneurodegeneration.com/content/8/1/36


Received:3 July 2013Accepted:23 September 2013Published:22 October 2013

© 2013 Lemere; licensee BioMed Central Ltd. 

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.